Search Site

Search form

Current Press Releases

View Summary Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis
Mar 28, 2017
PDF 103.1 KB
View Summary Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Mar 6, 2017
PDF 18.4 KB
View Summary Vertex to Present at the Cowen Healthcare Conference on March 6
Mar 2, 2017
PDF 7.8 KB
View Summary Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results
Jan 25, 2017
PDF 42.6 KB
View Summary Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex
Jan 11, 2017
PDF 15.3 KB
View Summary Vertex Provides Update on Business and Financial Performance and Research and Development Programs
Jan 8, 2017
PDF 34.5 KB
View Summary Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2016 Financial Results
Jan 4, 2017
PDF 8.3 KB
View Summary Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation
Dec 19, 2016
PDF 15.0 KB
View Summary Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017
Nov 7, 2016
PDF 66.2 KB
View Summary Vertex to Present at the Credit Suisse Healthcare Conference on November 8
Nov 2, 2016
PDF 7.8 KB
View Summary Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CF
Oct 27, 2016
PDF 74.5 KB
View Summary Vertex Reports Third Quarter 2016 Financial Results
Oct 25, 2016
PDF 45.0 KB
View Summary Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis
Oct 25, 2016
PDF 50.5 KB
View Summary Vertex to Announce Third Quarter 2016 Financial Results on October 25
Oct 7, 2016
PDF 7.9 KB
View Summary U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation
Sep 28, 2016
PDF 20.9 KB
View Summary Vertex to Present at Upcoming Investor Conferences
Sep 9, 2016
PDF 8.0 KB
View Summary Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
Aug 15, 2016
PDF 16.6 KB
Showing 1-17 of 17 Page: 1